Merrimack Pharmaceuticals, Inc. (MACK)
NASDAQ: MACK · IEX Real-Time Price · USD
14.74
+0.01 (0.07%)
Apr 26, 2024, 10:44 AM EDT - Market open
Company Description
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Merrimack Pharmaceuticals, Inc.
| Country | United States |
| IPO Date | Mar 29, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Gary L. Crocker M.B.A. |
Contact Details
Address: One Broadway, 14th Floor Cambridge, Massachusetts 02142 United States | |
| Phone | 617-441-1000 |
| Website | merrimack.com |
Stock Details
| Ticker Symbol | MACK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001274792 |
| CUSIP Number | 590328209 |
| ISIN Number | US5903282094 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gary L. Crocker M.B.A. | President, Treasurer, Principal Financial Officer, Principal Accounting Officer, Chief Executive Officer and Chairman |
| Dr. Ulrik B. Nielsen Ph.D. | Co-Founder and Independent Director |
| Dr. Anthony J. Sinskey Ph.D., Sc.D. | Co-Founder and Scientific Advisor |
| Timothy R. Surgenor | Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | DEFR14A | Filing |
| Mar 27, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 21, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 21, 2024 | 10-K/A | [Amend] Annual report |
| Mar 7, 2024 | 425 | Filing |
| Mar 7, 2024 | 8-K | Current Report |
| Mar 7, 2024 | 10-K | Annual Report |
| Mar 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |